Gasmi; Mehdi

Patent Applications and Registrations

Patent applications and USPTO patent grants for Gasmi; Mehdi.The latest application filed is for "treatment of amd using aav2 variant with aflibercept".

Company Profile

9.7.17

Gasmi; Mehdi - San Francisco CA
GASMI; Mehdi - San Diego CA
GASMI; MEHDI - BELMONT CA
Gasmi; Mehdi - Menlo Park CA
Gasmi; Mehdi - Sarasota FL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Mutant viral capsid libraries and related systems and methods Grant 11,427,931 - Chavez , et al. August 30, 2	2022-08-30
Treatment Of Amd Using Aav2 Variant With Aflibercept App 20220265740 - BLUMENKRANZ; Mark ; et al.	2022-08-25
Scalable Lentiviral Vector Production System Compatible With Industrial Pharmaceutical Applications App 20220235371 - MARCEAU; NICOLAS ; et al.	2022-07-28
Methods Of Treating Ocular Neovascular Diseases Using Aav2 Variants Encoding Aflibercept App 20210100856 - GASMI; Mehdi ; et al.	2021-04-08
Variant Aav Capsids For Intravitreal Delivery App 20200338146 - KERAVALA; Annahita ; et al.	2020-10-29
Sequential Intravitreal Administration Of Aav Gene Therapy To Contralateral Eyes App 20200297869 - CEPEDA; Diana ; et al.	2020-09-24
Mutant Viral Capsid Libraries And Related Systems And Methods App 20200149033 - CHAVEZ; Christopher ; et al.	2020-05-14
Mutant viral capsid libraries and related systems and methods Grant 10,584,328 - Chavez , et al.	2020-03-10
Scalable Lentiviral Vector Production System Compatible With Industrial Pharmaceutical Applications App 20190211360 - MARCEAU; NICOLAS ; et al.	2019-07-11
Gene Therapy For The Treatment Of Aldehyde Dehydrogenase Deficiency App 20190160187 - Gasmi; Mehdi ; et al.	2019-05-30
Treatment Of Amd Using Aav2 Variant With Aflibercept App 20190151409 - BLUMENKRANZ; Mark ; et al.	2019-05-23
Compositions And Methods For Reducing Ocular Neovascularization App 20190100582 - BLUMENKRANZ; Mark ; et al.	2019-04-04
Mutant Viral Capsid Libraries And Related Systems And Methods App 20170183647 - Chavez; Christopher ; et al.	2017-06-29
Scalable Lentiviral Vector Production System Compatible With Industrial Pharmaceutical Applications App 20140315294 - Marceau; Nicolas ; et al.	2014-10-23
Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein Grant 8,420,619 - Bartus , et al. April 16, 2	2013-04-16
Rescue Of Photoreceptors By Intravitreal Administration Of An Expression Vector Encoding A Therapeutic Protein App 20120316112 - Bartus; Raymond T. ; et al.	2012-12-13
Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein Grant 8,242,093 - Bartus , et al. August 14, 2	2012-08-14
Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of same Grant 8,092,429 - Gasmi , et al. January 10, 2	2012-01-10
Needle Assembly for Use in Delivering Precise Dosages of Proteinaceous Pharmaceutical Compositions and Methods for Use of Same App 20110060285 - Gasmi; Mehdi ; et al.	2011-03-10
Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of same Grant 7,837,668 - Gasmi , et al. November 23, 2	2010-11-23
Rescue of Photoreceptors by Intravitreal Administration of an Expression Vector Encoding a Therapeutic Protein App 20090202505 - Bartus; Raymond T. ; et al.	2009-08-13
Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of same App 20080086061 - Gasmi; Mehdi ; et al.	2008-04-10
Functional lentiviral vector from an MLV-based backbone App 20030003565 - Dubensky, Thomas W. JR. ; et al.	2003-01-02

Company Registrations

SEC

0001614875

Gasmi Mehdi

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.